IL-5, a cytokine mainly involved in the chemotaxis and activation of eosinophils, is also involved in the pathogenesis of EGPA; thus, targeting IL-5 or its receptor represent promising EGPA treatment strategies (Furuta et al., 2019; Vega Villanueva and Espinoza, 2020). Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.